The Leukemia and Lymphoma Society (LLS) is the largest global nonprofit whose efforts are focused on blood cancers. Their mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve quality of life for patients and their families. Beyond their continued financial support and dedication to research, LLS provides education and resources to patients, their families, and providers.
Since their foundation in 1949, LLS has provided up to 2 billion dollars towards groundbreaking and innovative cancer research, which has influenced current treatment practices. LLS has aided and financially supported 70 percent of the cancer therapies seen on the market today, most notably CAR- T cell therapy. Through grants and their Therapy Acceleration Program (TAP), LLS has changed the landscape of the chemotherapy market.
Beyond funding clinical research, LLS is also a fierce advocate for improving equity, access, and affordability of life- saving therapies for their patients. In addition to matching patients to cutting edge clinical trials, LLS also provides co- pay financial assistance to patients affected by blood cancers who may have trouble affording their treatments. Together with improving health equity, LLS provides a great number of resources including podcasts, peer- to- peer support groups, education on proper nutrition, among others.
LLS focuses deeply on pediatric patients affected by blood cancer because they are a unique subset of patients that are treated differently in all aspects of care. The Dare to Dream Initiative is newest phase of the LLS Children’s Initiative that aims to raise over 175 million dollars to expand research and treatment for pediatric blood cancers. One of the most notable facets of this program includes the creation of the first ever pediatric acute leukemia master trial (PEDAL) that matches patients to a trial that matches their specific cancer. Additionally, LLS is focusing on streamlining the gathering of pediatric AML data by facilitating the pediatric AML Data Commons.
The contributions that LLS has made through its efforts do not go unnoticed.
Citations:
“Leukemia & Lymphoma Society .” Leukemia & Lymphoma Society, Blood Cancer Leaders , LLS, www.lls.org. Accessed 13 Apr. 2024.
The Leukemia and Lymphoma Society
The Leukemia and Lymphoma Society (LLS) is the largest global nonprofit whose efforts are focused on blood cancers. Their mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve quality of life for patients and their families. Beyond their continued financial support and dedication to research, LLS provides education and resources to patients, their families, and providers.
Since their foundation in 1949, LLS has provided up to 2 billion dollars towards groundbreaking and innovative cancer research, which has influenced current treatment practices. LLS has aided and financially supported 70 percent of the cancer therapies seen on the market today, most notably CAR- T cell therapy. Through grants and their Therapy Acceleration Program (TAP), LLS has changed the landscape of the chemotherapy market.
Beyond funding clinical research, LLS is also a fierce advocate for improving equity, access, and affordability of life- saving therapies for their patients. In addition to matching patients to cutting edge clinical trials, LLS also provides co- pay financial assistance to patients affected by blood cancers who may have trouble affording their treatments. Together with improving health equity, LLS provides a great number of resources including podcasts, peer- to- peer support groups, education on proper nutrition, among others.
LLS focuses deeply on pediatric patients affected by blood cancer because they are a unique subset of patients that are treated differently in all aspects of care. The Dare to Dream Initiative is newest phase of the LLS Children’s Initiative that aims to raise over 175 million dollars to expand research and treatment for pediatric blood cancers. One of the most notable facets of this program includes the creation of the first ever pediatric acute leukemia master trial (PEDAL) that matches patients to a trial that matches their specific cancer. Additionally, LLS is focusing on streamlining the gathering of pediatric AML data by facilitating the pediatric AML Data Commons.
The contributions that LLS has made through its efforts do not go unnoticed.
Citations:
“Leukemia & Lymphoma Society .” Leukemia & Lymphoma Society, Blood Cancer Leaders , LLS, www.lls.org. Accessed 13 Apr. 2024.